The Priority Review

Clinical trials Brief

Intra-Cellular Therapies, Inc. posts results of Lumateperone schizophrenia relapse study

The Phase 3 study enrolled 592 participants and was completed with primary completion on July 25, 2024. Results were first posted on ClinicalTrials.gov on October 5, 2026.

Primary source

ClinicalTrials.gov results record, October 5, 2026

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation